Adding weekly paclitaxel to an experimental drug for advanced endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether adding weekly paclitaxel to an experimental drug called OK-1 can help treat advanced or recurrent endometrial cancer that has stopped responding to other treatments. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have endometrial cancer (including certain types like serous or clear cell) that is advanced, recurrent, or persistent and has not responded to standard treatments.
- You have received at least one platinum-based chemotherapy (like carboplatin or cisplatin) for recurrent or metastatic cancer, and no more than 5 prior treatment lines.
- You have received an immune checkpoint inhibitor (like pembrolizumab) as part of a previous treatment, unless you couldn't take it.
- You have tumor tissue available from a previous biopsy or surgery.
- You have measurable disease (tumors that can be seen on scans) and are in generally good health (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
This trial tests a new drug called BMX-001 combined with the chemotherapy drug paclitaxel for people with advanced ovarian or endometrial cancer that has come back or spread. The goal is to see if this combination can help control the cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.